Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown superiority compared to chemotherapy alone as first-line therapy in advanced non–small cell lung carcinoma (NSCLC). To evaluate the relative benefit in term of Overall Survival (OS) and Progression-free Survival (PFS) of c...
Main Authors: | Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00264/full |
Similar Items
-
Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
by: Marlies De Bock, et al.
Published: (2018-08-01) -
Multipl miyelom’da CD4+ regülatör T hücrelerin rolü
by: Deniz EKİNCİ, et al.
Published: (2017-09-01) -
FOCUS ON NIVOLUMAB IN NSCLC
by: Diego Luigi Cortinovis, et al.
Published: (2016-12-01) -
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
by: Huimei Yi, et al.
Published: (2021-05-01) -
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
by: Aleksandra Filipovic, et al.
Published: (2020-03-01)